About

The 3rd Oligonucleotides CMC and Analytical Development Summit covers topics such as: Regulatory Guidance for a New Era of Oligonucleotide Development, Outlining Current Industry Trends in Oligonucleotide Development, The Use of Risk Assessment to Evaluate the Quality Impact of Raw and Starting Materials Used in mRNA Manufacturing, Debating Analytical Methods and Validity for Alternate Oligonucleotide Types, Advancing Oligo-Conjugates Through Analytical Development, Ensuring Sequence Specificity as ASO Production Increases, Upstream Innovation: Analytical Development of Oligonucleotides to Enhance Processes, Strategies for Enhancing Oligonucleotide Drug Formulation With Patient Adherence in Mind, Application of NMR for PMO Characterization and Process Control Strategy, Delving Into Downstream AD and CMC Toolboxes, Development of AEX and HILIC as Orthogonal Separation Methods to IPRP for the Characterization of Purity and Impurities in Oligonucleotide Products to Ensure Quality, Development and Application of 2D HPLC for PMO Analysis and Impurity Profiling, Bridging the AD Gap to Simplify Development, Balancing Resolution and Equipment Complexity to Streamline Transfer to CMC Teams, Analytical Comparability for Tech Transfer and Process Change, Ensuring Reliable Product Quality to Facilitate Market Success, Process Development and Scale-up of GalNAc-Conjugated siRNA, Manufacturing Process Development for 2’-O-N-methylacetamide Oligonucleotides, Scalability and Process Economics Considerations for Oligonucleotides to Reach Additional Patient Groups, Back-Tracking Oligonucleotides for Process Validation and Improving Process Economics, Safe-Guarding Process Efficiency and Yield to Improve Cost, Looking Long-Term: Sustainability Strategies in Oligonucleotide Manufacturing to Minimize Environmental Impact, Implementing Ultrafiltration/Diafiltration for Processing ASOs to Improve Efficiency, Synthesis of RNA Fragments on a Soluble Support

Profile Details